Siblings Patents [0/8] Periodical Articles [119/120] Collection Statistics Item counts issued in 3 years:1(4.17%) Items With Fulltext:14(58.33%) Download counts of the item Download times greater than 0:14(100.00%) Download times greater than 100:14(100.00%) Total Bitstream Download Counts:7870(9.80%) Last Update: 2024-11-28 19:28 Top Upload Loading... Top Download Loading... Recent Submissions Discovery of novel AXL and MER inhi... BPR6K609: An Aurora kinase inhibito... Discovery of clinical candidate DBP... An Aurora kinase inhibitor BPR6K471... BPRDP056, a novel small molecule dr... 4-Bromophenylhydrazinyl benzenesulf... Optimization of quinazoline-based k... Discovery of BPR1K871-a quinazoline... Discovery and development of DBPR11... Novel cKIT kinase inhibitor, BPRCKJ...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1-24 of 24. (1 Page(s) Totally) 1  View [10|25|50] records per page

Date	Title	Relation
2023-10	Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs	Annals of Oncology. 2023 Oct;34(Suppl. 2):S214.
2020-08	BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification	Cancer Research. 2020 Aug;80(16):1937.
2019-10	Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer	Annals of Oncology. 2019 Oct;30(Suppl. 5):789.
2019-07	BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy	Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 227.
2019-07	An Aurora kinase inhibitor BPR6K471 inhibits tumor growth and reduces the cancer stem cell-like properties of small cell lung cancer	Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 3851.
2018-07	4-Bromophenylhydrazinyl benzenesulfonylphenylureas inhibit indoleamine 2,3-dioxygenase in vitro and in vivo	Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 1664.
2018-01	Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer	Cancer Science. 2018 Jan;109(Suppl. 1):739.
2017-04	Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482.
2016-12	Phenyl benzenesulfonylhydrazides: Selective indoleamine 2,3-dioxygenase inhibitors with potent in vivo pharmacodynamic activity and antitumor efficacy	European Journal of Cancer. 2016 Dec;68(Suppl. 1):S83-S84.
2016-12	Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P.
2015-08	Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform	Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413.
2015-08	Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
2014-11	Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent	European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
2014-10	Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
2014-03	DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
2013-11	A development drug candidate targeting EGFR kinase for lung cancer: DBPR112	Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.
2013-04-13	Exploration of the role of tylophorine E ring in anti-Coronavirus activity-Tylophorine derived dibenzoquinolines impart multi-biological activities as orally active agents	FASEB Journal. 2013 Apr 13;27:lb71.
2013-04-07	BPR000K, a novel Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
2013-04-07	3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI.
2013-04-07	Development drug candidate targeting EGFR kinase: DBPR112	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.
2012-11	BPR1J271, a novel FLT3 inhibitor for treating acute myeloid leukemia	European Journal of Cancer. 2012 Nov;48(Suppl. 6):53-54.
2011-03-27	Design and synthesis of potent Aurora kinase inhibitors	Abstracts of Papers - American Chemical Society. 2011 Mar 27;241:258-MEDI.
2011-03	Potent EGFR tyrosine kinase inhibitors as anticancer agents	Abstracts of Papers - American Chemical Society. 2011 Mar;241:257-MEDI.
2007-10	Differential effects of arsenic on cyp1 enzymes in vitro and in vivo	Drug Metabolism Reviews. 2007 Oct;39(Suppl. 1):209.

Showing items 1-24 of 24. (1 Page(s) Totally) 1  View [10|25|50] records per page